Veracyte raised full-year revenue guidance after a strong Q1, citing continued volume growth for key assays. Q1 revenue rose 21% to $139.1 million, with testing revenue increasing 26% to $135.1 million, led by Decipher prostate growth and Afirma thyroid classifier expansion.